AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Primary focus on pancreatic cancer

Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS

Read more at globenewswire.com